FLT3 and acute myeloid leukemia: Quizartinib was screened by the KinomeScan technique to improve the affinity and specificity to FLT3 kinase, and it showed strong activity and selectivity against FLT3-ITD but not TKD.109 The clinical efficacy of quizartinib was also superior to conventional chemotherapy (NCT00989261); therefore, it was approved for relapsed or refractory AML patients with FLT3-ITD mutations in 2019.110